	US 11,857,643 B2
	Compositions and methods for enhanced fluorescence
Surbhi Desai, Rockford, IL (US); Marie Christine Nlend, Rockford, IL (US); Kyle Gee, Springfield, OR (US); Matthew Baker, Rockford, IL (US); Robert Aggeler, Eugene, OR (US); Scott Sweeney, Eugene, OR (US); Aleksey Rukavishnikov, Eugene, OR (US); and Shih-Jung Huang, Eugene, OR (US)
Assigned to Life Technologies Corporation, Carlsbad, CA (US); and Pierce Biotechnology, Inc., Rockford, IL (US)
Filed by Life Technologies Corporation, Carlsbad, CA (US); and Pierce Biotechnology, Inc., Rockford, IL (US)
Filed on Mar. 11, 2020, as Appl. No. 16/816,015.
Application 16/816,015 is a division of application No. 15/693,772, filed on Sep. 1, 2017, abandoned.
Claims priority of provisional application 62/382,594, filed on Sep. 1, 2016.
Prior Publication US 2020/0261602 A1, Aug. 20, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 49/00 (2006.01); G01N 33/58 (2006.01); G01N 33/68 (2006.01); G01N 33/533 (2006.01); A61K 47/18 (2017.01); A61K 47/10 (2017.01)

CPC A61K 49/0015 (2013.01) [A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 49/0058 (2013.01); G01N 33/533 (2013.01); G01N 33/582 (2013.01); G01N 33/68 (2013.01)]

11 Claims

1. A method for increasing fluorescence of a first fluorescently labeled antibody, the method comprising:

(a) conjugating two or more spacer molecules to a first antibody; and

(b) conjugating from two to ten fluorescent labels to the first antibody;

wherein steps (a) and (b) are done simultaneously or sequentially in any order to form the first fluorescently labeled antibody;

wherein the spacer molecules and fluorescent labels are not conjugated to each other;

wherein the first fluorescently labeled antibody has a fluorescence that is greater than a fluorescence of a second fluorescently labeled antibody that comprises a second antibody that is the same as the first antibody and has the same number and type of fluorescent labels conjugated thereto, but does not include the spacer molecules conjugated to the second antibody; and

wherein the spacer molecules are selected from sulfo-NHS-acetate, MS(PEG)₄, or NHS-Betaine.